Alteplase for acute stroke revisited: the first 10 years

Lancet Neurology

Volumn 5, Issue 9, 2006, Pages 722-724

  Lyden, Patrick D ^a   Lees, Kennedy R ^b   Davis, Stephen M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TENECTEPLASE;

ACUTE DISEASE; BLOOD CLOT LYSIS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; IMAGING; LETTER; MEDICAL EDUCATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PATIENT SELECTION; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REPERFUSION; STROKE; THROMBUS; TREATMENT OUTCOME; TREATMENT PLANNING; UNCERTAINTY;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DELIVERY OF HEALTH CARE; FIBRINOLYTIC AGENTS; HUMANS; META-ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33746935556     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70530-0     Document Type: Letter

References (24)

1. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
2. Saver J. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 61 (2004) 1066-1070
3. Graham G. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 34 (2003) 2847-2850
4. Fagan S., Morgenstern L., Petitta A., et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50 (1998) 883-890
5. Nadareishvili Z., Oh P., Smurawska L., et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 52 (1999) 895-896
6. Sandercock P., Berge E., Dennis M., et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35 (2004) 1490-1497
7. Sinclair S., Frighetto L., Loewen P., et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19 (2001) 927-936
8. Lindley R., Wardlaw J., and Sandercock P. Alteplase and ischaemic stroke: have new reviews of old data helped?. Lancet Neurol 4 (2005) 249-253
9. Mayer S., Brun N., Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
10. Caplan L., Mohr J., Kistler J., and Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis-not a panacea for ischemic stroke. New Engl J Med 337 (1997) 1309-1310
11. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Stroke 28 (1997) 2119-2125
12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
13. Marler J., Tilley B., Lu M., et al. Early stroke treatment associated with better outcome. Neurology 55 (2000) 1649-1655
14. Davis S., Donnan G., Butcher K., and Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 18 (2005) 47-52
15. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
16. Barber P., Zhang J., Demchuk A., et al. Why are stroke patients excluded from TPA therapy?. Neurology 56 (2001) 1015-1020
17. Smith E., Abdullah A., Petkovska I., et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36 (2005) 2497-2499
18. Gilligan. Early CT changes do not predict parenchymal hemorrhage following streptokinase therapy in acute stroke. Stroke 31 (2000) 2887
19. von Kummer R., Allen K., Holle R., et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 205 (1997) 327-333
20. Patel S., Levine S., Tilley B., et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 286 (2001) 2830-2838
21. Ernst R., Pancioli A., Tomsick T., et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 31 (2000) 2552-2557
22. Lewandowski C., Frankel M., Tomsick T., et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Stroke 30 (1999) 2598-2605
23. Lees K., Zivin J., Ashwood T., et al. NXY-059 for acute ischemic stroke. N Engl J Med 354 (2006) 588-600
24. Haley Jr. E., Lyden P., Johnston K., and Hemmen T. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36 (2005) 607-612